Detralex, 500 mg 30 pcs.

Pharmgroup:

Venotonizing and venoprotective agent.

Pharmacological action:

DETRALEX has venotonic and angioprotective properties.

The drug reduces venous distensibility and venous stasis, decreases capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to indicators of venous hemodynamics.

A statistically significant dose-dependent effect of DETRALEX was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 2 tablets.

DETRALEX increases venous tone: venous occlusion plethysmography showed a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders a statistically significant increase of capillary resistance evaluated by angiostereometry after DETRALEX therapy was observed compared to placebo.

Therapeutic effectiveness of DETRALEX has been proven in treatment of chronic diseases of lower limb veins and in treatment of hemorrhoids.

Pharmacokinetics:

The main excretion of the drug is in the feces. With the urine on average about 14% of the taken amount of the drug is excreted.

The elimination half-life is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Indications

Symptomatic therapy of venous and lymphatic insufficiency, feeling of heaviness in the legs, pain, “Morning fatigue” of the legs, cramps, trophic disorders, symptomatic therapy of exacerbation of hemorrhoids.

Active ingredient

Composition

1 tablet contains:

Active ingredients:

purified micronized flavonoid fraction 500 mg ( including diosmin (90%) 450 mg,

Flavonoids expressed as hesperidin (10%) 50 mg);

Associates:

gelatin,

magnesium stearate,

microcrystalline cellulose,

sodium starch glycolate,

talc,

glycerol,

macrogol 6000,

Hydroxypropyl methylcellulose,

Iron oxide yellow (E172),

Red iron oxide (E172),

Titanium dioxide (E171),

Sodium lauryl sulfate.

How to take, the dosage

The drug is taken orally.

The recommended dose is 2 tablets per day, 1 tablet in the middle of the day and 1 tablet in the evening with meals.

In the period of exacerbation of hemorrhoids – 6 tablets per day for 4 days, then 4 tablets per day for the next 3 days.

Special Instructions

In acute hemorrhoids, prescribing this medication is not a substitute for specific treatment of other anal disorders. The duration of treatment should not exceed the recommended duration. If symptoms do not disappear after a short therapy, a proctologic examination should be performed and the therapy should be reviewed.

In the presence of venous circulatory disorders, the maximum effect of treatment is achieved in combination with a healthy, well-balanced lifestyle, in which it is advisable to avoid long exposures to the sun, reduce body weight, walk and in some cases wear special socks to improve blood circulation.

Impact on the ability to drive and operate machinery

The drug does not affect the ability to drive vehicles and perform work requiring high speed psychomotor reactions.

Contraindications

Hypersensitivity to the ingredients of the drug.

Side effects

CNS disorders: rarely – dizziness, headache, general malaise.

Gastrointestinal disorders: often – diarrhea, dyspepsia, nausea, vomiting; rarely – colitis.

The skin: rare – rash, itching, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids. In exceptional cases – angioedema.

Pregnancy use

Pregnancy

There have been no animal experiments showing teratogenic effects.

Till now there have been no reports of any side effects when using the drug in pregnant women.

Breast-feeding

Because of the lack of data concerning excretion of the drug into the breast milk, it is not recommended for breast-feeding women to take the drug.

Similarities